Taken together, NAFLD patients had lower adiponectin levels, and adiponectin had protective effects on the pathogenesis of NAFLD by activating PPAR-α and AMPK signaling pathways through AdipoR1 and AdipoR2. Here, PPARA is linked to metabolic dysfunction-associated steatotic liver disease.